Last reviewed · How we verify

Meningitis — Treatment Landscape & Competitive Intelligence

Meningitis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Meningitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Kanacin KANAMYCIN Bristol-Myers Squibb Aminoglycoside Antibacterial Gap junction beta-2 protein 1973-01-01
Eryped Erythromycin ethyl succinate Arbor Pharms Llc Macrolide 1965-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Meningitis
  2. Arbor Pharms Llc · 1 drug in Meningitis
  3. Bristol-Myers Squibb · 1 drug in Meningitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Meningitis:

Cite this brief

Drug Landscape (2026). Meningitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/meningitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing